Psilocybin Therapy for Alcohol Use Disorder

Psilocybin-assisted therapy for alcohol use disorder is the indication where psilocybin's published RCT evidence is stronger than ketamine's — a meaningful asymmetry within psychedelic medicine. The single most important trial is Bogenschutz et al. 2022, JAMA Psychiatry — a randomized double-blind trial in 95 patients with alcohol use disorder where two psilocybin sessions plus 12 weeks of structured psychotherapy reduced mean percentage of heavy drinking days to 9.7% versus 23.6% in the diphenhydramine-plus-same-psychotherapy arm over 32 weeks. This builds on Bogenschutz's earlier 2015 open-label proof-of-concept work. And yet — exactly as with ketamine — active substance use disorder is normally a contraindication for psilocybin therapy. Published trials enrolled detoxified, stabilized patients. Canadian SAP applications for AUD typically reflect this: documented stabilization, abstinence period, engagement with established addiction medicine and psychosocial recovery. Psilocybin is positioned as adjunctive consolidation work for committed-to-recovery patients, not as a detox tool, not as a replacement for naltrexone or acamprosate, and not as a first-line addiction treatment. This article walks through the evidence honestly.

Key takeaways

• The strongest evidence: Bogenschutz 2022 JAMA Psychiatry RCT (N=95) — two psilocybin sessions + 12 weeks psychotherapy reduced heavy drinking days to 9.7% vs 23.6% (diphenhydramine + same psychotherapy) over 32 weeks. This is the most rigorous published psilocybin SUD trial.
• Earlier proof of concept: Bogenschutz 2015 J Psychopharmacology open-label trial showed feasibility in detoxified AUD patients.
• Active SUD is normally a contraindication. All published psilocybin AUD trials enrolled detoxified, treatment-engaged patients. ATMA CENA's screening for SUD comorbidity reflects this — typically 30–90 days of documented abstinence with negative urine drug screening.
• Psilocybin is adjunctive, not first-line. Canadian addiction medicine standard remains naltrexone, acamprosate, psychosocial support (CRISM, AA, SMART Recovery). Psilocybin sits as consolidation work for stabilized patients with documented psychiatric comorbidity (depression, trauma) or persistent cravings interfering with recovery.
• SAP applications for AUD are less common than for end-of-life distress or TRD but documented in Canadian SAP authorizations since 2022.
• Psilocybin's AUD evidence is stronger than ketamine's at the individual-trial level (Bogenschutz 2022 vs Dakwar 2020 / KARE 2022) — but psilocybin is SAP-only access whereas ketamine is widely available off-label.

The paradox, stated honestly

Psilocybin is being studied for alcohol use disorder. It is also a Schedule III controlled substance with experiential effects that — like ketamine — would be unsafe to combine with active alcohol use or withdrawal. The published trials handled this paradox by enrolling detoxified patients who had completed acute withdrawal management before randomization. Canadian SAP-pathway clinicians follow the same principle: documented stabilization, abstinence, and integration with established addiction care.

Why active SUD is a contraindication:

1. Safety. Active alcohol use plus psilocybin's serotonergic effects creates unpredictable interactions; acute withdrawal (which can include seizures, autonomic instability, and delirium) requires medical detox before any psychiatric intervention.
2. Efficacy. The Bogenschutz 2022 protocol explicitly paired psilocybin sessions with 12 weeks of motivational enhancement therapy and cognitive-behavioural therapy. The benefit was not "psilocybin alone" — it was psilocybin plus structured psychotherapy in stabilized patients.
3. Neurobiology. Active heavy drinking disrupts the synaptic plasticity and neuroplastic mechanisms that psilocybin appears to engage. Stabilization is part of the therapeutic context.
4. Screening reality. No published psilocybin SUD trial enrolled actively-using patients. Real-world Canadian SAP-pathway clinics require documented abstinence, typically 30–90 days, with verification.

What psilocybin appears to be good for in AUD:

• Adjunctive consolidation in committed-to-recovery patients with documented depression, trauma, or persistent cravings interfering with recovery work.
• Particularly relevant for patients with comorbid TRD + AUD where the depression component is documented and contributing to relapse risk.
• Possibly useful for patients who have plateaued in standard AUD treatment despite engagement with addiction medicine and recovery infrastructure.

What psilocybin is not good for:

• Active alcohol use or recent acute withdrawal.
• Detox or withdrawal management — psilocybin does not reduce withdrawal symptoms.
• Replacing naltrexone, acamprosate, or psychosocial recovery support.
• Patients without an established recovery framework.

This framing parallels the ketamine-for-AUD paradox covered in Ketamine Therapy for Addiction.

What the evidence actually shows

Bogenschutz 2015 — proof of concept

Bogenschutz et al. 2015, Journal of Psychopharmacology — open-label trial in 10 patients with AUD using psilocybin (0.3 mg/kg, then 0.4 mg/kg if tolerated) integrated with motivational enhancement therapy. Significant reductions in drinking days, heavy drinking days, and craving were observed. As an open-label feasibility study, it established proof-of-concept for the modern psilocybin AUD model and informed the 2022 RCT design.

Bogenschutz 2022 JAMA Psychiatry — the pivotal RCT

Bogenschutz et al. 2022, JAMA Psychiatry — randomized double-blind clinical trial in 95 patients with AUD across two academic sites (NYU and University of New Mexico). Protocol:

• Detoxified, treatment-engaged patients (key context for the SUD paradox).
• Two psilocybin sessions (25 mg/70 kg first session; 25–40 mg/70 kg second session) versus diphenhydramine 50–100 mg active comparator.
• Both arms received 12 weeks of structured psychotherapy — motivational enhancement therapy and cognitive-behavioural therapy.
• Primary outcome: percentage of heavy drinking days over 32 weeks of follow-up.

Findings:

• Mean percentage of heavy drinking days: 9.7% (psilocybin arm) versus 23.6% (diphenhydramine arm) — a substantial and statistically significant difference.
• Reductions in drinks per drinking day, drinks per week, and craving.
• No serious adverse events related to psilocybin.
• Sustained difference between arms across the follow-up period.

This is the single most rigorous published psychedelic SUD trial. It is why psilocybin's AUD evidence is described as stronger than ketamine's at the individual-trial level.

Comparison to ketamine AUD evidence

The honest framing: psilocybin has cleaner published RCT evidence for AUD specifically; ketamine has broader real-world Canadian access. Patients evaluating both should consider evidence base, access pathway, comorbidity profile (TRD + AUD favours either; trauma comorbidity may inform), and clinical fit.

For the cross-treatment comparison, see Psilocybin vs Ketamine Therapy and Ketamine Therapy for Addiction.

Recent and ongoing work

Phase 3 work on psilocybin for AUD is in development through multiple sponsors. Bogenschutz and the NYU group continue ongoing follow-up and protocol refinement. Roots to Thrive (Nanaimo BC) has expanded their SAP-pathway clinical work to include AUD case-by-case. A larger meta-analytic synthesis of psilocybin SUD evidence remains an open research domain.

How psilocybin appears to work in AUD

The mechanistic story applies to AUD as it does to other indications:

• 5-HT2A serotonin receptor agonism triggers downstream glutamate, AMPA, BDNF, and synaptogenesis effects.
• Default mode network modulation (Carhart-Harris 2012) — DMN deactivation may interrupt the rumination and craving loops that maintain addiction.
• Mystical-type experience as mediator (Roseman 2018) — quality of acute experience predicts therapeutic outcomes; in Bogenschutz 2022, mystical experience intensity correlated with drinking-day outcomes.
• Therapeutic alliance and integration — psilocybin's effects are paired with motivational enhancement and CBT in published protocols; integration sessions translate insights into behavior change.

The honest framing: the mechanism is plausible and supported by converging evidence, but the why does this work in AUD specifically question — beyond general psychedelic therapy effects — remains under investigation. The Bogenschutz protocol's pairing of psilocybin with established AUD psychotherapy (MET + CBT) is part of the active ingredient.

Canadian addiction medicine context

Standard Canadian AUD treatment frameworks remain unchanged by psilocybin's emergence:

• First-line pharmacotherapy: naltrexone, acamprosate; topiramate or gabapentin in some cases.
• Psychosocial support: motivational interviewing, cognitive-behavioural therapy, 12-step (AA) or SMART Recovery participation.
• Medical detox as needed for moderate-to-severe withdrawal.
• CRISM (Canadian Research Initiative on Substance Misuse) publishes the national Canadian AUD treatment guidelines.

Psilocybin sits outside these standard frameworks. CRISM and CCSA (Canadian Centre on Substance Use and Addiction) do not currently endorse psilocybin for AUD. Health Canada SAP applications for AUD are case-specific and reflect:

• Documented AUD diagnosis (DSM-5 criteria).
• Documented stabilization (abstinence period, engagement with addiction care).
• Documented inadequate response to standard treatments.
• Comorbid psychiatric conditions (depression, trauma) that strengthen the case for psilocybin's evidence base.
• Prescribing physician willing to initiate SAP application.

The clinically-defensible pathway for psilocybin in AUD is as adjunctive consolidation work for stabilized patients on standard addiction medicine, with documented psychiatric comorbidity or persistent cravings interfering with recovery.

How ATMA CENA supports SAP-pathway AUD patients

ATMA CENA's screening for SUD comorbidity follows the published trial logic:

1. Diagnostic and current status: DSM-5 SUD diagnosis; current vs documented abstinence; recent use timeline.
2. Abstinence period: typically 30–90 days documented abstinence with negative urine drug screening before psilocybin work is considered. Specific duration is individualized.
3. Established addiction care: engagement with addiction medicine (naltrexone, acamprosate); psychosocial support (AA, SMART Recovery, individual addiction counsellor); a primary recovery framework. Psilocybin does not replace these.
4. Comorbid psychiatric diagnosis: TRD or trauma comorbidity is the most common ATMA CENA-suitable profile; the comorbid condition is often the primary indication with AUD as concurrent.
5. Misuse risk assessment: history of psychedelic misuse is a relative contraindication; structured supervised dosing and no take-home dispensing are part of safe practice.
6. Coordinated care plan: ATMA CENA + addiction physician + therapist + community recovery support all in coordination via release-of-information.

For patients who have stabilized in recovery and are evaluating whether psilocybin is the right adjunctive next step, ATMA CENA intake call works through these elements honestly.

Frequently asked questions

Is psilocybin therapy approved for alcohol use disorder? No — psilocybin has no Health Canada-approved indication. AUD-specific access is via Special Access Program (SAP) only, with prescribing physician initiation. Standard AUD pharmacotherapy in Canada is naltrexone, acamprosate, with psychosocial support.

Why is active alcohol use a contraindication? Safety (interactions, withdrawal management requires medical detox), efficacy (the therapeutic value depends on stabilization and integration psychotherapy that requires sobriety), neurobiology (active heavy drinking disrupts the plasticity psilocybin engages), and screening reality (the Bogenschutz 2022 trial enrolled detoxified patients).

How long do I need to be abstinent before psilocybin therapy? Typically 30–90 days documented abstinence with negative urine drug screening, individualized to substance, severity, and stability. ATMA CENA's intake call works through this with you.

Can psilocybin help me detox? No. Psilocybin is not a detox medication. It does not reduce withdrawal symptoms from alcohol. Standard medical detox approaches (often inpatient with appropriate pharmacotherapy) remain the entry point before any psychiatric intervention.

Does psilocybin replace naltrexone or acamprosate? No. Naltrexone and acamprosate remain first-line AUD pharmacotherapy in Canadian guidelines. Psilocybin is not a replacement and may be considered as adjunct in stabilized patients with documented psychiatric comorbidity.

Does psilocybin replace AA or SMART Recovery? No. Community recovery infrastructure is part of the standard of care. Psilocybin is adjunctive to — not replacement for — psychosocial recovery support.

Is psilocybin AUD evidence stronger than ketamine's? At the individual-trial level, yes — Bogenschutz 2022 JAMA Psychiatry (N=95) is the most rigorous published psychedelic SUD trial, with substantial effect sizes over 32 weeks. Ketamine's strongest published AUD evidence is the KARE trial (Grabski 2022, N=96) and Dakwar 2020. Both molecules show real effects; psilocybin's RCT base is cleaner. But access differs — ketamine is broadly available off-label in Canada; psilocybin is SAP-only.

Can I do psilocybin therapy if I have comorbid TRD and AUD? This is the most common ATMA CENA-suitable profile. Comorbid TRD + AUD typically frames the SAP application around the depression component, with AUD addressed via integrated addiction care. Psilocybin's evidence in both indications supports this profile.

What's the SAP approval rate for AUD applications? SAP authorizations for AUD specifically have been less common than for end-of-life distress or TRD. Approval depends on documented stabilization, comorbidity, prior treatment failures, and a willing prescribing physician. PsyCan reported overall SAP approval declines through 2025.

What if I have AUD plus trauma history? Trauma comorbidity is common in AUD and is part of the screening and preparation conversation. PTSD-specific psychedelic SAP applications more commonly target MDMA-assisted therapy than psilocybin in current Canadian practice — see Ketamine Therapy for PTSD for the trauma-pathway context.

Where can I access psilocybin AUD therapy in Canada? Through SAP-authorized clinicians with addiction-medicine experience or psychiatric training in interventional work. TheraPsil maintains a directory; some Canadian providers (Roots to Thrive, Numinus-network providers) have SAP-pathway AUD experience. ATMA CENA supports preparation and integration via coordinated care in coordination with the patient's addiction medicine team.

What about psilocybin for opioid use disorder or stimulant use disorder? Less evidence than for AUD. Opioid use disorder standard care remains buprenorphine/naloxone or methadone with psychosocial support. Stimulant use disorder has no approved pharmacotherapy; psilocybin SAP applications for stimulant use disorder are uncommon. Ketamine has somewhat more cocaine-specific evidence (Dakwar 2014, 2019). See Ketamine Therapy for Addiction.

Sources

1. ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
2. Bogenschutz MP, et al. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/25586396/
3. Bogenschutz MP, et al. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625
4. Carhart-Harris RL, et al. (2012). Neural correlates of the psychedelic state — DMN. PNAS. https://pubmed.ncbi.nlm.nih.gov/22308440/
5. Roseman L, Nutt DJ, Carhart-Harris RL (2018). Quality of acute psychedelic experience predicts therapeutic efficacy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29387009/
6. Grabski M, et al. (2022). Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder (KARE) — comparison context. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/34855456/
7. Dakwar E, et al. (2020). Single ketamine infusion + MET for alcohol use disorder — comparison context. Am J Psychiatry. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.2019.18101123
8. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
9. CRISM — Canadian AUD treatment guidelines: https://crism.ca/
10. Canadian Centre on Substance Use and Addiction (CCSA): https://www.ccsa.ca/

Related articles in this cluster

• Psilocybin Therapy in Canada
• What Is Psilocybin Therapy?
• How to Access Psilocybin Therapy in Canada (SAP)
• Psilocybin Therapy for Treatment-Resistant Depression
• Psilocybin vs Ketamine Therapy
• Ketamine Therapy for Addiction
• Ketamine vs Psilocybin Therapy
• Find care near you

Last updated: 2026-05-06